Mapping the human genetic architecture of COVID-19
…, AL Fracanzani, A Peschuck, A Pesenti, C de la Horra… - Nature, 2021 - nature.com
The genetic make-up of an individual contributes to the susceptibility and response to viral
infection. Although environmental, clinical and social factors have a role in the chance of …
infection. Although environmental, clinical and social factors have a role in the chance of …
[HTML][HTML] Pneumocystis jirovecii in general population
…, M Montes-Cano, M Conde, C De la Horra… - Emerging infectious …, 2005 - ncbi.nlm.nih.gov
The possible presence of Pneumocystis among healthy adults was examined by detecting
Pneumocystis jirovecii–specific DNA in prospectively obtained oropharyngeal wash samples …
Pneumocystis jirovecii–specific DNA in prospectively obtained oropharyngeal wash samples …
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
…, C Maj, C Ferrando, C de la Horra… - Human molecular …, 2022 - academic.oup.com
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a
deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our …
deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our …
Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease Who Are Colonized with Pneumocystis jiroveci
…, JM Varela, FJ Medrano, C De La Horra - Clinical Infectious …, 2007 - academic.oup.com
In chronic obstructive pulmonary disease, high levels of airway and systemic inflammatory
markers are associated with a faster decrease in lung function. Our study shows that patients …
markers are associated with a faster decrease in lung function. Our study shows that patients …
Update on Dihydropteroate Synthase (DHPS) Mutations in Pneumocystis jirovecii
A Pneumocystis jirovecii is one of the most important microorganisms that cause
pneumonia in immunosupressed individuals. The guideline for treatment and prophylaxis of …
pneumonia in immunosupressed individuals. The guideline for treatment and prophylaxis of …
[HTML][HTML] Changing trends in the epidemiology and risk factors of Pneumocystis pneumonia in Spain
…, F Moreno-Verdejo, C De la Horra… - Frontiers in public …, 2019 - frontiersin.org
Objective: The information about the epidemiology of Pneumocystis pneumonia (PcP) in
Europe is scarce, and in Spain there are only data nationwide on patients with HIV infection. …
Europe is scarce, and in Spain there are only data nationwide on patients with HIV infection. …
[HTML][HTML] Vertical transmission of Pneumocystis jirovecii in humans
…, M Fontillon-Alberdi, C de la Horra… - Emerging infectious …, 2009 - ncbi.nlm.nih.gov
To the Editor: Currently, animal and human studies favor an airborne transmission pattern
for Pneumocystis pneumonia (1). However, the early age of acquisition of Pneumocystis spp. …
for Pneumocystis pneumonia (1). However, the early age of acquisition of Pneumocystis spp. …
HLA‐A*11:01 and HLA‐C*04:01 are associated with severe COVID‐19
…, J De la Cruz Troca, C de la Horra, AB de la Hoz… - HLA, 2023 - Wiley Online Library
We analyzed the association between HLA polymorphisms and susceptibility to SARS‐CoV‐2
infection and disease severity. Genotyping data from a total of 9373 COVID‐19‐positive …
infection and disease severity. Genotyping data from a total of 9373 COVID‐19‐positive …
[HTML][HTML] Pneumocystis jirovecii transmission from immunocompetent carriers to infant
L Rivero, C de la Horra, MA Montes-Cano… - Emerging infectious …, 2008 - ncbi.nlm.nih.gov
We report a case of Pneumocystis jirovecii transmission from colonized grandparents to their
infant granddaughter. Genotyping of P. jirovecii showed the same genotypes in samples …
infant granddaughter. Genotyping of P. jirovecii showed the same genotypes in samples …
Pneumocystis jirovecii colonization in patients treated with infliximab
…, FJ Medrano, LZ Goldani, C de la Horra… - European journal of …, 2011 - Wiley Online Library
Eur J Clin Invest 2011; 41 (3): 343–348 Abstract Background Infliximab, a chimeric antitumour
necrosis factor (TNF) monoclonal antibody, has become an established effective therapy …
necrosis factor (TNF) monoclonal antibody, has become an established effective therapy …